logo-loader
RNS
Tristel PLC

Tristel PLC - Confirmation of CEO Transition, Directorate Change

RNS Number : 3937C
Tristel PLC
02 September 2024
 

 

Tristel plc

("Tristel" or the "Company")

 

Confirmation of CEO Transition and Directorate Change

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, confirms that Matt Sassone has today assumed his position of CEO of Tristel, following Paul Swinney's retirement, as previously announced on 10 June 2024.

 

The Company also announces that Bart Leemans will step down from the Tristel Board as an Executive Director. He will remain with the business and continue to focus his efforts on the French market in his capacity as Managing Director, Tristel SAS. There are no current plans to replace Bart on the Tristel Board.

 

Bart was appointed in November 2018 following Tristel's acquisition of his business, the Ecomed Group, the Company's then distributor in Belgium, the Netherlands and France. The French market continues to represent significant untapped growth potential for the Company; sales in France during the year ended 30 June 2024 were £3.0 million, approximately 7% of the Group's total of £41.9 million, compared with 13% of Group sales generated in Germany and 39% in the UK.

 

Bruno Holthof, Chair of Tristel, commented: "I would like to welcome Matt to our Company, and also thank Bart for his contribution to the Board during his tenure. He has brought with him great entrepreneurial spirit and drive and I am pleased that he will continue to contribute to the growth of the business through dedicating his efforts to the French market."

 

 

For further information please contact:  

  

Tristel plc

Via Walbrook PR

Matt Sassone, Chief Executive Officer

www.investors.tristel.com

Liz Dixon, Chief Financial Officer


 


Walbrook PR Ltd

Tel: 020 7933 8780 or tristel@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Charlotte Edgar

Mob: 07884 664 686



Cavendish Capital Markets Limited

Tel: 020 7220 0500

Geoff Nash, Camilla Hume/Trisyia Jamaludin (Corporate Finance)


Sunila de Silva (Corporate Broking)


 


The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation ("MAR") EU no.596/2014. Upon the publication of this announcement via Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

 

About Tristel plc

Tristel plc is a global infection prevention company focussed on the manufacture and supply of products using its unique proprietary chlorine dioxide (ClO2) chemistry. The Company is a market leader in manual decontamination of medical devices, supplying hospitals under the Tristel brand, and under the Cache brand provides products for sporicidal surface disinfection, in a format which is a sustainable alternative to commonly used pre-wetted plastic wipes.

 

Tristel's head office and manufacturing facility is located in Snailwell, near Cambridge, and operates globally employing approximately 250 people across 14 subsidiaries selling into 40 countries.

 

The Company has been listed on the London Stock Exchange's AIM market since 2005 (AIM: TSTL).

 

For more information about Tristel's product range please visit: https://tristel.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAURRNRSBUWOAR
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

3 min read